

Article

Furanocoumarins from *Ruta chalepensis* with Amebicide Activity

Aldo Fabio Bazaldúa-Rodríguez ^{1,*}, Ramiro Quintanilla-Licea ^{1,*}, María Julia Verde-Star ¹,
Magda Elizabeth Hernández-García ², Javier Vargas-Villarreal ³ and Jesús Norberto Garza-González ⁴

- ¹ Laboratorio de Fitoquímica, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León (UANL), Av. Universidad S/N, Cd. Universitaria, San Nicolás de los Garza C.P. 66455, Nuevo León, Mexico; aldo.bazalduarg@uanl.edu.mx (A.F.B.-R.); maria.verdest@uanl.edu.mx (M.J.V.-S.)
- ² Laboratorio de Fisiología Celular y Molecular, Centro de Investigaciones Biomédicas del Noreste (CIBIN), Dos de Abril Esquina con San Luis Potosí, Monterrey C.P. 64720, Nuevo León, Mexico; magda.hernandezgr@uanl.edu.mx
- ³ Laboratorio de Biología y Fisiología Molecular y Celular, Centro de Investigaciones Biomédicas del Noreste (CIBIN), Dos de Abril Esquina con San Luis Potosí, Monterrey C.P. 64720, Nuevo León, Mexico; jvargas147@yahoo.com.mx
- ⁴ Departamento de Ciencias Básicas, Universidad de Monterrey, Av. Ignacio Morones Prieto 4500 Pte., San Pedro Garza García C.P. 66238, Nuevo León, Mexico; jesu.n.garza@udem.edu
- * Correspondence: ramiro.quintanillalc@uanl.edu.mx; Tel.: +(52)-81-83763668



Citation: Bazaldúa-Rodríguez, A.F.; Quintanilla-Licea, R.; Verde-Star, M.J.; Hernández-García, M.E.; Vargas-Villarreal, J.; Garza-González, J.N. Furanocoumarins from *Ruta chalepensis* with Amebicide Activity. *Molecules* **2021**, *26*, 3684. <https://doi.org/10.3390/molecules26123684>

Academic Editors: Giovanni Lentini, Maria Maddalena Cavalluzzi, Solomon Habtemariam and Francesca Mancianti

Received: 17 May 2021
Accepted: 13 June 2021
Published: 16 June 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: *Entamoeba histolytica* (protozoan; family Endamoebidae) is the cause of amoebiasis, a disease related to high morbidity and mortality. Nowadays, this illness is considered a significant public health issue in developing countries. In addition, parasite resistance to conventional medicinal treatment has increased in recent years. Traditional medicine around the world represents a valuable source of alternative treatment for many parasite diseases. In a previous paper, we communicated about the antiprotozoal activity in vitro of the methanolic (MeOH) extract of *Ruta chalepensis* (Rutaceae) against *E. histolytica*. The plant is extensively employed in Mexican traditional medicine. The following workup of the MeOH extract of *R. chalepensis* afforded the furocoumarins rutamarin (**1**) and chalepin (**2**), which showed high antiprotozoal activity on *Entamoeba histolytica* trophozoites employing in vitro tests (IC₅₀ values of 6.52 and 28.95 µg/mL, respectively). Therefore, we offer a full scientific report about the bioguided isolation and the amebicide activity of chalepin and rutamarin.

Keywords: parasitic diseases; amoebiasis; Mexican traditional medicine; bioguided isolation; natural products; antiprotozoal agents

1. Introduction

Amoebiasis is the term for a parasitic infection triggered by the protozoan *Entamoeba histolytica*. This disease represents one of the most widespread parasite maladies in developing countries [1,2], making it a significant public health problem [3,4].

In Mexico, this infection is considered an endemic illness [5–7] and represents the most common parasitic disease found in the general population [8,9]. It is also more frequently found in the intestinal amoebiasis of Mexican children, especially newborn and school children [10].

Amoebiasis frequently produces an intestinal infection that can transform into an extra-intestinal infection throughout the portal veins, affecting the liver and producing a more significant hepatic lesion, in addition to lesions in the lungs, skin, and brain [11,12]. Following malaria, amoebiasis represents the second leading factor of death caused by parasite infections [13]. Nearly 50 million people develop acute amoebiasis, and 40,000–100,000 deaths caused by this sickness happen per year worldwide [14,15].

It is important to highlight that the chemotherapy used against *E. histolytica* has shown significant advancement. Nevertheless, the treatment's abandonment produces chronic patients, illness propagators, and develops a multidrug resistance parasite [10,16].


The most utilized therapeutic drug for the medication of this infection is metronidazole, but, owing to the drug's undesired side effects [17,18] and considering the burgeon of resistant strains of *E. histolytica* against it, new antiprotozoal agents are required [19,20]. Plants are a good source of natural products that have been used in the treatment of protozoa illness [21–24], and Mexican traditional medicine can offer many plants that could be useful for developing treatment against *E. histolytica* [25]. In a previous paper, we discussed the antiamoebic activity in vitro of the MeOH extract of *Ruta chalepensis* [26]. *Ruta chalepensis* is a Mediterranean plant introduced in Mexico and used by different ethnic groups to treat gastrointestinal illnesses such as stomachache, diarrhea, dysentery, and nausea [27]. Additionally, there are reports of emmenagogue, anthelmintic, antirheumatic, antihypertensive, abortive, and anti-inflammatory activity for this plant [28,29]. *R. chalepensis* possess many known furanocoumarins, coumarins, alkaloids, quinoline alkaloids, and flavonoids distributed in leaves, stems, and roots [28,30,31].

This research aims to isolate and identify substances responsible for the amebicide activity of *R. Chalepensis*.

2. Results

2.1. Bioguided Isolation of Furanocoumarins from *Ruta chalepensis*

The following diagram (Figure 1) shows the number of chromatography columns implemented (silica gel or Sephadex), as well as the percentage of inhibition against *E. histolytica* of the most relevant fractions during the bioguided fractionation of the MeOH extract of *R. chalepensis* to obtain the furanocoumarins Rutamarin (1) and Chalepin (2) in high purity (TLC; see Supplementary Materials).



* Growth inhibition on *E. histolytica* at 150 $\mu\text{g/mL}$. **Growth inhibition on *E. histolytica* less than 50% at 150 $\mu\text{g/mL}$. ^{NA} No amebicide activity

Figure 1. General scheme for the bioguided isolation of compounds with antiamoebic activity from *Ruta chalepensis*.

Both compounds were characterized by different spectroscopic techniques.

The unambiguous assignment of the ^{13}C -NMR spectrum of the isolated furanocoumarins was obtained from ^1H - ^1H COSY, NOESY, HSQC, and HMBC spectra (see Supplementary Material).

Rutamarin (1) was recovered as a white amorphous solid (m. p. $104\text{ }^\circ\text{C}$; Lit. $107\text{--}109\text{ }^\circ\text{C}$; [32]. The spectroscopy data of this compound corresponded to a previous compound reported as rutamarin, 1 [32].

Chalepin (2) was obtained as a yellow amorphous solid (m. p. $125\text{--}126\text{ }^\circ\text{C}$; Lit. $117\text{--}118\text{ }^\circ\text{C}$) [33]. The spectroscopy data of this compound corresponded to a previous compound reported as chalepin, 2 [34].

Both compounds are structurally related to chalepinsin (3), a furanocoumarin also occurring in this plant [26]. See Figure 2.




Figure 2. Structure of furanocoumarins isolated from *Ruta chalepensis* with amebicide activity.

2.2. Determination of IC_{50} for Rutamarin (1) and Chalepin (2)

The in vitro assay for the isolated furanocoumarins against trophozoites of *E. histolytica* showed significant activity.

Figures 3 and 4 show the 50% inhibitory concentration of each compound calculated using a probit analysis, considering a 95% confidence level.




Figure 3. Antiprotozoal activity of Rutamarin 1 against *Entamoeba histolytica*. 90.03% Growth inhibition at $150\text{ }\mu\text{g/mL}$, $\text{IC}_{50} = 6.52\text{ }\mu\text{g/mL}$ ($18.29\text{ }\mu\text{M}$).




Figure 4. Antiprotozoal activity of Chalepin 2 against *Entamoeba histolytica* 94.50% Growth inhibition at 150 µg/mL, IC₅₀ = 28.95 µg/mL (92.08 µM).

3. Discussion

Ruta chalepensis is a medicinal plant used worldwide for its wide range of medicinal purposes [35]. However, the antiparasitic activity against *Entamoeba histolytica* of this plant has not been sufficiently disclosed in ethnobotanical reports until now. Antiparasitic activity of *R. chalepensis* has been previously evaluated on helminths of veterinary importance [36,37] and protozoa of clinical importance such as *Leishmania infantum*, *L. major* [38] and *Giardia lamblia* [39,40]. The antiparasitic activity over *E. histolytica* by the methanolic crude extract was previously reported [26], showing moderate activity with an IC₅₀ of 60.07 µg/mL. The antiparasitic activity of the furanocoumarin chalepensisin (3), isolated from the hexane partition of *R. chalepensis* by Quintanilla-Licea et al. [26], was also moderate, showing an IC₅₀ of 45.95 µg/mL. The antiamebic activity of rutamarin (1) and chalepin (2) isolated in this research work is slightly higher (IC₅₀ of 6.52 and 28.95 µg/mL, respectively) but far less effective than metronidazole (IC₅₀ 0.205 µg/mL) [26]. We can therefore consider the three furanocoumarins as responsible for the antiparasitic activity of *R. chalepensis*. Furanocoumarins are part of the chemical components with the most significant presence in *R. chalepensis* [41]. Rutamarin (1) and chalepin (2) have been previously isolated from this plant [42]; our research group briefly described the amebicide activity of these furanocoumarins at a scientific congress [43,44]. We are now offering a full scientific report about the bioguided isolation and identification of these amebicide compounds. These results may support the use of *R. chalepensis* as an alternative treatment for amoebiasis in traditional Mexican medicine, as it is for other plants of equal importance [45,46]. The toxic activity of coumarins on eukaryotic cells has received an important analysis suggesting a partial mechanism of action for compounds of this nature where cell injury is caused by damage to DNA [47]. Chalepin (2) has shown specific toxicity on normal cells and cancer cell lines, for example HT29 human colon carcinoma cells with cytotoxic activity by 55.1 µM. Although rutamarin (1), in some analyses, showed selectivity with its cytotoxic activity at a concentration of 1.12 µM, it was also reported that it generates significant alterations in the cell growth of BCBL-1 cells at a concentration of 5.60 µM [48,49]. A certain toxicity on normal mammalian cells at the respective concentrations of the IC₅₀ of compounds 1 and 2 (18.29 and 92.08 µM, respectively) could be expected. The furanocoumarins isolated from *R. chalepensis* (1-3) have outstanding antiamebic activity, but the presence of an acetyl group in rutamarin may increase the antiparasitic activity, producing a better complex with DNA and therefore causing more considerable cellular damage [47].

4. Materials and Methods

4.1. General Experimental Procedures

NMR spectra were acquired on an Avance DPX 400 Spectrometer (Bruker, Billerica, MA, USA) working at 400.13 MHz for ^1H and 100.61 MHz for ^{13}C . Melting points were measured on Electrothermal 9100 equipment (Electrothermal Engineering Ltd., Southend-on-Sea, UK).

Thin-layer chromatography (TLC) was developed on pre-coated silica gel plates (Merck, Kenilworth, NJ, USA Silica Gel 60 F254). Visualization of the components of the crude extract or pure compounds was made using UV light. Open column chromatography was implemented with silica gel of a 60–200 mesh (J. T. Baker, Phillipsburg, NJ, USA) and Sephadex LH-20 (Sigma-Aldrich, St. Louis, MO, USA, LH20100-500G).

4.2. Plant Material

R. chalepensis, *L. Rutaceae* was collected near the city of Aramberri, Nuevo León State in northern Mexico, 24°19'13" N, 99°54'55" W. It was dried using a light chamber at 38 °C and was then powdered with a manual grain. Plant material was placed at the herbarium of the Facultad de Ciencias Biológicas in the Universidad Autónoma de Nuevo León, with a register number 025579.

4.3. Drugs and Reagents

The bioassay was made in the PEHPS medium, provided by the Centro de Investigación Biomédica del Noreste, IMSS [50]. CTR[®] Scientific (Mexico) purchased organic solvents: *n*-hexane, chloroform (CHCl_3), Ethyl acetate (EtOAc), Methanol (MeOH), and dimethyl sulfoxide (DMSO).

4.4. Extraction of Plant Material from *R. chalepensis*

Six hundred grams of leaves and stems from *R. chalepensis* were dried and powdered, separated in packets of 60 g, and subjected to extraction with 600 mL of MeOH, each using Soxhlet equipment for 40 h. The MeOH was eliminated in a rotary evaporator. The crude extract was preserved at 4 °C until it was needed.

4.5. Parasite and In Vitro Amebicide Assay

4.5.1. Microorganisms

The trophozoites of *Entamoeba histolytica* (strain HM-1:IMSS) were acquired from the Centro de Investigación Biomédica del Noreste (CIBIN) microorganism culture collection in Monterrey (Mexico). The parasites were grown axenically and kept up in peptone combined with pancreas extract, liver extract and bovine serum (PEHPS medium, so designated based on the Spanish initials of its major components). The microorganisms were utilized at the log phase of growth (2×10^4 cells/mL) by all of the tests carried out [51,52].

Next, 2×10^5 trophozoites of *E. histolytica* in 5 mL of the PEHPS medium (with the 10% bovine serum added) were inoculated in 13 mm $\times$ 100 mm screw cap test tubes and incubated at 36.5 °C for 120 h to establish the growth curve for *E. histolytica*. Every 24 h, the number of trophozoites was evaluated to determine the medium's growth parameters [53]. The procedure was performed in 3 separate assays per triplicate.

4.5.2. In Vitro Test for *Entamoeba histolytica*

Each sample was dissolved in the DMSO and standardized to 150 $\mu\text{g/mL}$ by adding a mixture of *E. histolytica* trophozoites at a logarithmic phase in the PEHPS medium with the 10% bovine serum. Afterward, vials were incubated for 72 h and then introduced into iced water for 20 min. The number of dead trophozoites per milliliter was estimated by using a hemocytometer. Each assay was implemented in triplicate. The positive control was metronidazole. The negative control was an *E. histolytica* suspension in the PEHPS medium.

with no extract added. The percentage of inhibition was determined by evaluating the number of dead trophozoites in the samples and the negative controls [53].

4.5.3. In Vitro IC₅₀ Evaluation

Each sample was dissolved in the DMSO and standardized to 150, 75, 37.5, 18.75, and 9.375 µg/mL by adding a mixture of *E. histolytica* trophozoites at a logarithmic phase in the PEHPS medium with the 10% bovine serum. Afterward, vials were incubated for 72 h and then introduced into iced water for 20 min. The number of dead trophozoites per milliliter was estimated by using a hemocytometer. Each assay was implemented in triplicate. The positive control was Metronidazole. The negative control was an *E. histolytica* suspension in the PEHPS medium with no extract added. The percentage of inhibition was determined by evaluating the number of dead trophozoites in the samples and the negative controls. The 50% inhibitory concentration of each sample was determined using a probit analysis, taking into account a 95% confidence level [53].

4.6. Bioassay-guided Fractionation

The crude MeOH extract of *R. chalepensis* (124 g) with an amebicide activity of 90.50% at 150 µg/mL [26] was dissolved again in one L methanol and distributed into four portions of 250 mL, each to make a liquid–liquid partition with *n*-hexane (750 mL each portion). The hexane partition was evaporated under vacuum. Column chromatography on the silica gel of this hexane residuum led to the isolation of chalepensisin (3), Figure 1 [26]. The MeOH phase was then concentrated under vacuum until obtaining 50 mL and was added drop by drop into 200 mL of distilled water under continuous agitation. The resulting suspension was put through a liquid–liquid partition with EtOAc (750 mL). After EtOAc evaporation, 20.0 g of a resin with a good amebicide activity (84.82% of growth inhibition at 150 µg/mL) was obtained. The EtOAc partition was distributed in ten portions of 2 g; each one were subjected to open column chromatography (30 cm × 2 cm) on the silica gel (25 g each), eluting with stepwise gradients of CHCl₃–EtOAc (100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100 *v/v*, each at 50 mL) and EtOAc–MeOH (100:0, 90:10, 80:20, 70:30, 60:40, 50:50 *v/v*, each at 50 mL). All fractions obtained were gathered and pooled based on their TLC (CHCl₃–EtOAc; 9.5:0.5) profile to yield nine fractions (A1–A9). The in vitro amebicide assay exhibited that A3 and A4 had the highest growth of inhibition (95.84% and 94.18%, respectively). The fraction A3 (1.55 g) was subjected to open column chromatography on the silica gel, eluting with gradients of CHCl₃–EtOAc (100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60 *v/v*; each at 50 mL). The fractions were gathered and pooled based on their TLC (CHCl₃–EtOAc; 9.5:0.5) profile in five fractions (B1–B5). The fraction B2 (716 mg) with the best amebicide activity (an 81.75% growth inhibition) was submitted to open column chromatography on the silica gel, eluting with gradients of CHCl₃–EtOAc (100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100 *v/v*; each at 50 mL). The fractions obtained were collected and pooled on their TLC (CHCl₃–EtOAc; 9.5:0.5) profile in four fractions (C1–C4). The fraction C2 (540 mg, a 92.01% growth inhibition) was submitted to open column chromatography on the silica gel, eluting with gradients of CHCl₃–EtOAc (100:0, 99:01, 95:05, 90:10, 85:15, 80:20, 70:30, 60:40 *v/v*; each at 50 mL). The fractions obtained were collected and pooled on their TLC (CHCl₃–EtOAc; 9.5:0.5) profile in three fractions (D1–D3). The fraction D2 (499 mg, an 86.72% growth inhibition) was subjected to crystallization in methanol, obtaining a white amorphous solid (365 mg, an 88.56% growth inhibition), which was submitted to open column chromatography on Sephadex LH-20, eluting with MeOH. The fractions obtained were gathered and pooled on their TLC (CHCl₃–EtOAc; 9.5:0.5) profile in five fractions (E1–E5). Fraction E2 afforded 252 mg pure rutamarin (1), Figure 2, with a 90.03% growth inhibition. IC₅₀ = 6.52 µg/mL (18.29 µM). *R*_f = 0.66 (CHCl₃:EtOAc, 9.5:0.5).

The fraction A4 (476 mg) with an 94.18% of amebicide activity was submitted to open column chromatography on the silica gel, eluting with stepwise gradients of CHCl₃–EtOAc (100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, *v/v*, each at 50 mL). The obtained fractions

were collected and pooled using the information obtained from their TLC profile in six fractions (F1–F6). The fraction F4 (193 mg, an 89.43% growth inhibition) was subjected to open column chromatography on Sephadex LH-20, using methanol as an eluent. The fractions obtained were collected and pooled on their TLC (CHCl_3 -EtOAc; 9:1) profile into four fractions (G1–G4). The fraction G2 (81 mg, a 90.41% growth inhibition) was submitted to open column chromatography on Sephadex LH-20, using methanol as an eluent. The fractions obtained were collected and pooled on their TLC (CHCl_3 -EtOAc; 9.5:0.5) profile in four fractions (H1–H3). Fraction H2 afforded 66 mg pure chalepin (**2**), Figure 3, with a 94.50% growth inhibition. IC_{50} = 28.95 $\mu\text{g/mL}$ (92.08 μM). R_f = 0.38 (CHCl_3 :EtOAc, 9:1).

5. Conclusions

This study describes the bioguided isolation [54] of two amebicide constituents of *R. chalepensis*. The furanocoumarins rutamarin (**1**) and chalepin (**2**) represent the most active chemical components of *R. chalepensis* against the protozoa *E. histolytica* with IC_{50} values of 6.52 and 28.95 $\mu\text{g/mL}$, respectively. To the best of our knowledge, this is the first report about the amebicide activity of chalepin and rutamarin. Even though the amebicide activity of both compounds are far less effective than metronidazole (IC_{50} 0.205 $\mu\text{g/mL}$), the IC_{50} values obtained in our research for rutamarin and chalepin may also be used as the basis for incorporating *Ruta chalepensis* extracts into conventional and complementary medicine for the therapy of amoebiasis and other infectious diseases.

Supplementary Materials: The following are available online: Supplementary spectroscopic data. Figure S1. ^1H -NMR spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S2. Expansion in the area from 1.2–3.4 ppm. ^1H -NMR spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S3. Expansion in the area from 4.8–7.6 ppm. ^1H -NMR spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S4. COSY spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S5. ^{13}C -NMR spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 100 MHz. (CDCl_3), Figure S6. Expansion in the area from 0.5–60 ppm ^{13}C -NMR spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 100 MHz. (CDCl_3), Figure S7. DEPT 135 spectrum from ^{13}C -NMR spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 100 MHz. (CDCl_3), Figure S8. HSQC spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S9. Expansion in the area ^1H : 1.3–3.4 ppm, ^{13}C : 15–45 ppm. HSQC spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S10. Expansion in the area ^1H : 4.6–8.0 ppm, ^{13}C : 20–50 ppm. HSQC spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S11. Expansion in the area ^1H : 4.6–8.0 ppm, ^{13}C : 80–150 ppm. HSQC spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S12. Expansion in the area ^1H : 0.8–2.6 ppm, ^{13}C : 15–50 ppm. HMBC spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S13. Expansion in the area ^1H : 0.4–3.5 ppm, ^{13}C : 80–106 ppm. HMBC spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S14. Expansion in the area ^1H : 0.4–3.4 ppm, ^{13}C : 110–190 ppm. HMBC spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S15. Expansion in the area ^1H : 1.8–8.0 ppm, ^{13}C : 70–105 ppm. HMBC spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S16. Expansion in the area ^1H : 2.5–8.0 ppm, ^{13}C : 110–175 ppm. HMBC spectrum of **1**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S17. ^1H -NMR spectrum of **2**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S18. Expansion in the area from 2.5–8.0 ppm. ^1H -NMR spectrum of **2**. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl_3), Figure S19. COSY spectrum of **2**. Obtained by a Bruker

Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S20. Expansion in the area 1H: 5.6–8.0 ppm, 13C: 5.6–8.0 ppm. COSY spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S21. 13C-NMR spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 100 MHz. (CDCl₃), Figure S22. DEPT 135 spectrum from 13C-NMR spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 100 MHz. (CDCl₃), Figure S23. HSQC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S24. Expansion in the area 1H: 1.0–3.4 ppm, 13C: 15–50 ppm. HSQC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S25. Expansion in the area 1H: 1.0–3.4 ppm, 13C: 15–50 ppm. HSQC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S26. Expansion in the area 1H: 4.0–7.5 ppm, 13C: 85–120 ppm. HSQC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S27. Expansion in the area 1H: 3.6–6.0 ppm, 13C: 95–120 ppm. HSQC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S28. Expansion in the area 1H: 6.8–8.0 ppm, 13C: 130–170 ppm. HSQC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S29. Expansion in the area 1H: 5.6–8.2 ppm, 13C: 130–170 ppm. HSQC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S30. HMBC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S31. Expansion in the area 1H: 0.9–1.9 ppm, 13C: 20–45 ppm. HMBC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S32. Expansion in the area 1H: 1.0–3.4 ppm, 13C: 70–130 ppm. HMBC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S33. Expansion in the area 1H: 0.9–1.8 ppm, 13C: 120–185 ppm. HMBC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S34. Expansion in the area 1H: 4.6–7.6 ppm, 13C: 20–50 ppm. HMBC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S35. Expansion in the area 1H: 4.6–8.5 ppm, 13C: 70–128 ppm. HMBC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S36. Expansion in the area 1H: 4.6–7.6 ppm, 13C: 120–165 ppm. HMBC spectrum of 2. Obtained by a Bruker Spectrometer Model Advance DPX400, 9.4 Teslas. Operating frequency 400 MHz. (CDCl₃), Figure S37. NMR Data of Rutamarin (1) and Chalepin (2), Figure S38. Antiprotozoal activity of Rutamarin (1) against trophozoite of *E. histolytica*. T = negative control consisting of culture medium and parasites, Figure S39. Antiprotozoal activity of Chalepin (2) against trophozoite of *E. histolytica*. T = negative control consisting of culture medium and parasites, Figure S40. General scheme for the bioguided isolation of compounds with antiamoebic activity from *Ruta chalepensis*.

Author Contributions: Conceptualization, R.Q.-L. and A.F.B.-R.; Investigation, J.V.-V., M.J.V.-S., M.E.H.-G., and J.N.G.-G.; Writing—review and editing, R.Q.-L. and A.F.B.-R., R.Q.-L. conceived and designed the experiments; R.Q.-L., A.F.B.-R. and M.J.V.-S. performed the extraction and isolation; R.Q.-L. and A.F.B.-R. performed the spectral analysis and structure determination; J.V.-V., M.E.H.-G., and J.N.G.-G. conceived, designed, and performed the antiprotozoal assay; R.Q.-L., and A.F.B.-R. wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We acknowledge CONACYT (Mexico) for the doctoral fellowship awarded to Aldo Fabio Bazaldúa Rodríguez and the support given throughout the development of this research project. We also thank Benito David Mata-Cardenas and Javier Vargas-Villarreal for providing the

protozoa *E. histolytica* used in this research. We thank H. Laatsch of the University of Göttingen (Germany) for the spectroscopic measurements.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available from the authors.

References

1. Carrero, J.C.; Reyes-López, M.; Serrano-Luna, J.; Shibayama, M.; Unzueta, J.; León-Sicaire, N.; de la Garza, M. Intestinal amoebiasis: 160 years of its first detection and still remains as a health problem in developing countries. *Int. J. Med. Microbiol.* **2020**, *310*, 15138. [CrossRef] [PubMed]
2. Da-Silva-Alves, E.B.; Conceição, M.J.; Silva, V.L.; Monteiro-Fonseca, A.B.; Leles, D. What is the future of intestinal parasitic diseases in developing countries? *Acta Trop.* **2017**, *171*, 6–7. [CrossRef] [PubMed]
3. Babuta, M.; Bhattacharya, S.; Bhattacharya, A. *Entamoeba histolytica* and pathogenesis: A calcium connection. *PLoS Pathog.* **2020**, *16*, e1008214. [CrossRef] [PubMed]
4. Manna, D.; Ehrenkaufer, G.M.; Lozano-Amado, D.; Singh, U. *Entamoeba* stage conversion: Progress and new insights. *Curr. Opin. Microbiol.* **2020**, *58*, 62–68. [CrossRef]
5. Caballero-Salcedo, A.; Viveros-Rogel, M.; Salvatierra, B.; Tapia-Conyer, R.; Sepulveda-Amor, J.; Gutierrez, G.; Ortiz-Ortiz, L. Seroepidemiology of amebiasis in Mexico. *Am. J. Trop. Med. Hyg.* **1994**, *50*, 412–419. [CrossRef]
6. Ramos, F.; Morán, P.; González, E.; García, G.; Ramiro, M.; Gómez, A.; García De León, M.D.C.; Melendro, E.I.; Valadez, A.; Ximénez, C. High Prevalence Rate of *Entamoeba histolytica* asymptomatic infection in a rural Mexican community. *Am. J. Trop. Med. Hyg.* **2005**, *73*, 87–91. [CrossRef]
7. Azam, A.; Agarwal, S. Targeting amoebiasis: Status and developments. *Curr. Bioact. Compd.* **2007**, *3*, 121–133. [CrossRef]
8. Davila-Gutierrez, C.E.; Vasquez, C.; Trujillo-Hernandez, B.; Huerta, M. Nitazoxanide compared with quinifamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. *Am. J. Trop. Med. Hyg.* **2002**, *66*, 251–254. [CrossRef]
9. Moran, P.; Ramos, F.; Ramiro, M.; Curiel, O.; González, E.; Valadez, A.; Gómez, A.; García, G.; Melendro, E.I.; Ximénez, C. *Entamoeba histolytica* and/or *entamoeba dispar*: Infection frequency in HIV+/AIDS patients in Mexico city. *Exp. Parasitol.* **2005**, *110*, 331–334. [CrossRef]
10. Romero-Cabello, R.; Roberto-Guerrero, L.; Martínez-Barbosa, I.; Vázquez-Tsuji, O.; Ruiz-Sánchez, D.; Tay-Zavala, J.; Sánchez-Vega, J.T.; Calderón-Romero, L. Evaluation of the efficacy and security of quinifamide administered in a single dose of 300 mg in adult patients with intestinal amebiasis. *Parasitol. Latinoam.* **2005**, *60*, 57–60. [CrossRef]
11. González-Vázquez, M.C.; Carabarin-Lima, A.; Baylón-Pacheco, L.; Talamás-Rohana, P.; Rosales-Encina, J.L. Obtaining of three recombinant antigens of *Entamoeba histolytica* and evaluation of their immunogenic ability without adjuvant in a hamster model of immunoprotection. *Acta Trop.* **2012**, *122*, 169–176. [CrossRef]
12. Salles, J.M.; Moraes, L.A.; Salles, M.C. Hepatic amebiasis. *Braz. J. Infect. Dis.* **2003**, *7*, 96–110. [CrossRef]
13. Aguilar-Rojas, A.; Olivo-Marin, J.C.; Guillen, N. The motility of *Entamoeba histolytica*: Finding ways to understand intestinal amoebiasis. *Curr. Opin. Microbiol.* **2016**, *34*, 24–30. [CrossRef]
14. Institut-Pasteur Amoebiasis. Available online: <https://www.pasteur.fr/en/medical-center/disease-sheets/amoebiasis-0> (accessed on 6 January 2021).
15. Uddin, M.J.; Leslie, J.L.; Petri, W.A., Jr. Host protective mechanisms to intestinal amebiasis. *Trends Parasitol.* **2020**, *36*, 1–11. [CrossRef]
16. Orozco, E.; López, C.; Gómez, C.; Pérez, D.G.; Marchat, L.; Bañuelos, C.; Delgadillo, D.M. Multidrug resistance in the protozoan parasite *Entamoeba histolytica*. *Parasitol. Int.* **2002**, *51*, 353–359. [CrossRef]
17. Motazedian, M.H.; Mohammadpour, N.; Khabnadideh, S. Efficacy of some metronidazole derivatives against *Giardia lamblia*, in vivo study. *Trends Pharm. Sci.* **2015**, *1*, 149–152.
18. Bendesky, A.; Menéndez, D. Metronidazol: Una visión integral. *Rev. Fac. Med. UNAM* **2001**, *44*, 255–259.
19. Wassmann, C.; Hellberg, A.; Tannich, E.; Bruchhaus, I. Metronidazole resistance in the protozoan parasite *Entamoeba histolytica* is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. *J. Biol. Chem.* **1999**, *274*, 26051–26056. [CrossRef]
20. Bansal, D.; Malla, N.; Mahajam, R.C. Drug resistance in amoebiasis. *Indian J. Med. Res.* **2006**, *123*, 115–118.
21. Calzada, F.; Meckes, M.; Mata, R. Screening of Mexican medicinal plants for antiprotozoal activity. *Pharm. Biol.* **1998**, *36*, 305–309. [CrossRef]
22. Tapia-Pérez, M.E.; Tapia-Contreras, A.; Cedillo-Rivera, R.; Osuna, L.; Meckes, M. Screening of Mexican medicinal plants for antiprotozoal activity—Part II. *Pharm. Biol.* **2003**, *41*, 180–183. [CrossRef]
23. Bautista, E.; Calzada, F.; Yépez-Mulia, L.; Bedolla-García, B.Y.; Fragosó-Serrano, M.; Pastor-Palacios, G.; González-Juárez, D.E. *Salvia connivens*, a source of bioactive flavones with amoebicidal and giardicidal activity. *Rev. Bras. Farmacogn.* **2020**, *30*, 729–732. [CrossRef]

24. Martínez-Castillo, M.; Pacheco-Yepez, J.; Flores-Huerta, N.; Guzmán-Téllez, P.; Jarillo-Luna, R.A.; Cárdenas-Jaramillo, L.M.; Campos-Rodríguez, R.; Shibayama, M. Flavonoids as a natural treatment against *Entamoeba histolytica*. *Front. Cell. Infect. Microbiol.* **2018**, *8*, 1–14. [\[CrossRef\]](#) [\[PubMed\]](#)
25. Calzada, F.; Bautista, E. Plants used for the treatment of diarrhoea from Mexican flora with amoebicidal and giadicidal activity, and their phytochemical constituents. *J. Ethnopharmacol.* **2020**, *253*, 1–4. [\[CrossRef\]](#)
26. Quintanilla-Licea, R.; Mata-Cárdenas, B.D.; Vargas-Villarreal, J.; Bazaldúa-Rodríguez, A.F.; Ángeles-Hernández, I.K.; Garza-González, J.N.; Hernández-García, M.E. Antiprotozoal activity against *Entamoeba histolytica* of plants used in northeast Mexican traditional medicine. Bioactive compounds from *Lippia graveolens* and *Ruta chalepensis*. *Molecules* **2014**, *19*, 21044–21065. [\[CrossRef\]](#)
27. Heinrich, M.; Ankli, A.; Frei, B.; Weimann, C.; Sticher, O. Medicinal plants in Mexico: Healers' consensus and cultural importance. *Soc. Sci. Med.* **1998**, *47*, 1859–1871. [\[CrossRef\]](#)
28. Mejri, J.; Abderrabba, M.; Mejri, M. Chemical composition of the essential oil of *Ruta chalepensis* L: Influence of drying, hydro-distillation duration and plant parts. *Ind. Crop. Prod.* **2010**, *32*, 671–673. [\[CrossRef\]](#)
29. Gonzales, J.; Benavides, V.; Rojas, R.; Pino, J. Efecto embriotóxico y teratogénico de *Ruta chalepensis* L. «ruda», en ratón (*Mus musculus*). *Rev. Peru. Biol.* **2006**, *13*, 223–225. [\[CrossRef\]](#)
30. El Sayed, K.; Al-Said, M.S.; El-Feraly, F.S.; Ross, S.A. New quinoline alkaloids from *Ruta chalepensis*. *J. Nat. Prod.* **2000**, *63*, 995–997. [\[CrossRef\]](#)
31. Ulubelen, A.; Öztürk, M. Alkaloids and coumarins from *Ruta* species. *Nat. Prod. Commun.* **2006**, *1*, 851–857. [\[CrossRef\]](#)
32. Wu, T.S.; Shi, L.S.; Wang, J.J.; Iou, S.C.; Chang, H.C.; Chen, Y.P.; Kuo, Y.H.; Chang, Y.L.; Teng, C.M. Cytotoxic and antiplatelet aggregation principles of *Ruta graveolens*. *J. Chin. Chem. Soc.* **2003**, *50*, 171–178. [\[CrossRef\]](#)
33. Ezmirly, S.T.; Wilson, S.R. Saudi Arabian medicinal plants I: *Ruta chalepensis*. *J. Chem.* **1980**, *2*, 55–57.
34. Richardson, J.S.M.; Sethi, G.; Lee, G.S.; Malek, S.N.A. Chalepin: Isolated from *Ruta angustifolia* L. pers induces mitochondrial mediated apoptosis in lung carcinoma cells. *BMC Complement. Altern. Med.* **2016**, *16*, 1–27. [\[CrossRef\]](#)
35. Coimbra, A.T.; Ferreira, S.; Duarte, A.P. Genus *Ruta*: A natural source of high value products with biological and pharmacological properties. *J. Ethnopharmacol.* **2020**, *260*, 113076. [\[CrossRef\]](#)
36. Akkari, H.; Ezzine, O.; Dhahri, S.; Rekik, M.; Hajaji, S.; Aziz Darghouth, M.; Lahbib Ben Jamâa, M.; Gharbi, M. Chemical composition, insecticidal and in vitro anthelmintic activities of *Ruta chalepensis* (Rutaceae) essential oil. *Ind. Crop. Prod.* **2015**, *74*, 745–751. [\[CrossRef\]](#)
37. Ortu, E.; Sanna, G.; Scala, A.; Pulina, G.; Caboni, P.; Battaccone, G. In vitro anthelmintic activity of active compounds of the fringed rue *Ruta chalepensis* against dairy ewe gastrointestinal nematodes. *J. Helminthol.* **2017**, *91*, 447–453. [\[CrossRef\]](#)
38. Ben Hadj Ahmed, S.; Sghaier, R.M.; Guesmi, F.; Kaabi, B.; Mejri, M.; Attia, H.; Laouini, D.; Smaali, I. Evaluation of antileishmanial, cytotoxic and antioxidant activities of essential oils extracted from plants issued from the leishmaniasis-endemic region of Sned (Tunisia). *Nat. Prod. Res.* **2011**, *25*, 1195–1201. [\[CrossRef\]](#) [\[PubMed\]](#)
39. Calzada, F.; Meckes, M.; Cedillo-Rivera, R. Antiamoebic and anti-giardial activity of plant flavonoids. *Planta Med.* **1999**, *65*, 78–80. [\[CrossRef\]](#)
40. Calzada, F.; Yépez-Mulia, L.; Aguilar, A. In vitro susceptibility of *Entamoeba histolytica* and *Giardia lamblia* to plants used in Mexican traditional medicine for the treatment of gastrointestinal disorders. *J. Ethnopharmacol.* **2006**, *108*, 367–370. [\[CrossRef\]](#)
41. Günaydin, K.; Savci, S. Phytochemical studies on *Ruta chalepensis* (LAM.) lamarck. *Nat. Prod. Res.* **2005**, *19*, 203–210. [\[CrossRef\]](#)
42. Ulubelen, A.; Terem, B.; Tuzlaci, E.; Cheng, K.F.; Kong, Y.C. Alkaloids and coumarins from *Ruta chalepensis*. *Phytochemistry* **1986**, *25*, 2692–2693. [\[CrossRef\]](#)
43. Quintanilla-Licea, R.; Mata-Cárdenas, B.D.; Vargas-Villarreal, J.; Bazaldúa-Rodríguez, A.F.; Verde-Star, M.J. Antiprotozoal activity against *Entamoeba histolytica* of furocoumarins isolated from *Ruta chalepensis*. *Planta Med.* **2016**, *81*, S1–S381. [\[CrossRef\]](#)
44. Nahar, L.; Al-Majmaie, S.; Al-Groshi, A.; Rasul, A.; Sarker, S.D. Chalepin and chalepsin: Occurrence, biosynthesis and therapeutic potential. *Molecules* **2021**, *26*, 1609. [\[CrossRef\]](#) [\[PubMed\]](#)
45. Calzada, F.; Velázquez, C.; Cedillo-Rivera, R.; Esquivel, B. Antiprotozoal activity of the constituents of *Teloxys graveolens*. *Phytother. Res.* **2003**, *17*, 731–732. [\[CrossRef\]](#)
46. Calzada, F.; Cervantes-Martínez, J.A.; Yépez-Mulia, L. In vitro antiprotozoal activity from the roots of *Geranium mexicanum* and its constituents on *Entamoeba histolytica* and *Giardia lamblia*. *J. Ethnopharmacol.* **2005**, *98*, 191–193. [\[CrossRef\]](#)
47. Fadlalla, K.; Watson, A.; Yehualaeshet, T.; Turner, T.; Samuel, T. *Ruta graveolens* extract induces DNA damage pathways and blocks akt activation to inhibit cancer cell proliferation and survival. *Anticancer Res.* **2011**, *31*, 233–241.
48. Xu, B.; Wang, L.; González-Molleda, L.; Wang, Y.; Xu, J.; Yuan, Y. Antiviral activity of (+)-Rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II. *Antimicrob. Agents Chemother.* **2014**, *58*, 563–573. [\[CrossRef\]](#) [\[PubMed\]](#)
49. Suhaimi, S.A.; Hong, S.L.; Malek, N.A. Rutamarin, an active constituent from *Ruta angustifolia* Pers., induced apoptotic cell death in the HT29 colon adenocarcinoma cell line. *Pharmacogn. Mag.* **2017**, *13*, 179–188.
50. Said-Fernández, S.; Vargas-Villarreal, J.; Castro-Garza, J.; Mata-Cárdenas, B.D.; Navarro-Marmolejo, L.; Lozano-Garza, G.; Martínez-Rodríguez, H. PEHPS medium: An alternative for axenic cultivation of *Entamoeba histolytica* and *E. invadens*. *Trans. R. Soc. Trop. Med. Hyg.* **1988**, *82*, 249–253. [\[CrossRef\]](#)

-
51. Mata-Cárdenas, B.D.; Vargas-Villarreal, J.; González-Salazar, F.; Palacios-Corona, R.; Salvador, S.-F. A new vial microassay to screen antiprotozoal drugs. *Pharmacologyonline* **2008**, *1*, 529–537.
 52. González-Salazar, F.; Mata-Cárdenas, B.D.; Vargas-Villarreal, J. Sensibilidad de trofozoitos de *Entamoeba histolytica* a ivermectina. *Medicina* **2009**, *69*, 318–320. [[PubMed](#)]
 53. Quintanilla-Licea, R.; Vargas-Villarreal, J.; Verde-Star, M.J.; Rivas-Galindo, V.M.; Torres-Hernández, Á.D. Antiprotozoal activity against *Entamoeba histolytica* of flavonoids isolated from *Lippia graveolens* kunth. *Molecules* **2020**, *25*, 2464. [[CrossRef](#)] [[PubMed](#)]
 54. Alsayari, A.; Kopel, L.; Ahmed, M.S.; Soliman, H.S.M.; Annadurai, S.; Halaweish, F.T. Isolation of anticancer constituents from *Cucumis prophetarum* var. *prophetarum* through bioassay-guided fractionation. *BMC Complement. Altern. Med.* **2018**, *18*, 1–12. [[CrossRef](#)]